| INTRODUCTION
Pulmonary arterial hypertension (PAH) is a progressive disease process associated with pulmonary vascular remodeling and right heart failure that carries a high morbidity and mortality. 1, 2 Although pulmonary artery pressures, functional capacity assessments, and patient symptoms are used to guide therapies, prognostication can still be challenging. 1, [3] [4] [5] Studies have identified age, blood pressure, renal function, and biomarker abnormalities as predictors of adverse prognosis, and these clinical variables can be helpful in discussing prognosis with patients and guiding therapy. 6 Although serum albumin concentration has been found to be an important prognostic indicator in numerous other disease processes, limited data are available in the PAH population. 1, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] In patients with chronic heart failure, lower serum albumin levels have been associated with poor prognosis. [10] [11] [12] [13] 21 Similarly, in patients with congenital heart disease, lower albumin levels were more commonly seen with greater disease complexity. 14 Despite several studies examining the relationship between hypoalbuminemia and outcomes in heart failure patients, no study has systematically assessed the prognostic significance of albumin in a contemporary chronic PAH population. We therefore sought to investigate whether hypoalbuminemia is associated with worse long-term outcomes in PAH patients. Demographics of the final study population of 163 patients with a documented serum albumin level are shown in Table 1 . Most patients were female (74%), with a mean age of 52.3 AE14.6 years.
| METHODS
Most patients reported NYHA functional class II to III symptoms. Noninvasive and invasive hemodynamic measurements are noted in Table 2 ; the average mean PA pressure was severely elevated at 48 AE16 mm Hg. Echocardiographic right ventricular dilatation (50%) and systolic dysfunction (44%) were common, with 20% of patients demonstrating a significant pericardial effusion on echocardiography.
Mean serum albumin was 3.8 AE0.8 g/dL. The 41 (25.2%) patients with serum albumin in the bottom quartile (≤3.3 g/dL) were considered to have hypoalbuminemia (group 1) and were compared to the remaining patients (group 2). Table 1 illustrates clinical differences between patients with and without hypoalbuminemia. Patients with hypoalbuminemia had a shorter duration since PAH diagnosis than the remaining patients (1.7 years vs 2.7 years, P = 0.009) and more frequently had a prior diagnosis of cirrhosis (29% vs 7%, P < 0.001) and CKD (27% vs 10%, P = 0.007). Serum creatinine (1.4 vs 1.1 mg/ dL, P = 0.012) and blood urea nitrogen (26 vs 20 mg/dL, P = 0.044) levels were higher in patients with hypoalbuminemia, whereas hemoglobin was lower (11.6 vs 13.4 g/dL, P < 0.001). Echocardiographic and invasive right heart catheterization-derived hemodynamic assessments were similar between groups. Patients with hypoalbuminemia were more likely to have a significant pericardial effusion (34% vs 15%, P = 0.005) ( Table 2) .
Serum albumin was a significant univariate predictor of mortality (P = 0.01); the optimal serum albumin cutoff for predicting mortality based on receiver operating characteristic curve analysis was 3.3 g/ dL. Table 3 b Invasive right heart hemodynamic catheterization measurement. Abbreviations: 6MWD, 6-minute walk distance; BUN, blood urea nitrogen; NYHA, New York Heart Association; PDE5, phosphodiesterase 5. Data presented as mean AE standard deviation or n (%).
| DISCUSSION
This is the largest reported study evaluating the prognostic value of serum albumin concentrations among patients with PAH. This is the first study to systematically describe the relevance of serum albumin levels for long-term prognosis in a contemporary PAH population. Our results demonstrate that lower albumin levels portend worse survival outcomes, and are associated with the presence of other systemic comorbidities that may reflect a more rapid disease progression. Albumin is the most abundant serum protein, exclusively synthesized in the liver and subsequently secreted into the plasma, entering both the intra-and extravascular spaces. 20 Serum albumin levels are influenced by numerous factors that may influence patient outcomes, including nutritional status, inflammatory state, and liver function. 22 Liver dysfunction does not appear to be the most important determinant of decreased serum albumin levels in some disease processes, implicating other pathophysiologic mechanisms. 22, 23 Breakdown of albumin occurs in intravascular compartments, likely with a large component derived from endothelial cells as well as capillary leakage.
Heart failure patients may have an increased transcapillary escape rate of albumin, which is associated with higher right atrial pressures. 12 In animal studies, decreased albumin increases permeability in the lung vasculature, promoting pulmonary edema. 19 In patients with PAH, endothelial dysfunction and capillary leakage are common, which has been hypothesized to mediate loss of plasma proteins. 20 Additionally, increased severity in endothelial dysfunction and damage creates the platform for hypoalbuminemia. 23 Therefore, a diminished amount of circulating albumin likely plays a role in the pathophysiology surrounding PAH, potentially as both a cause and consequence of disease progression.
We found no difference among hemodynamic and functional capacity metrics as a function of serum albumin levels, except for a larger predisposition to a significant pericardial effusion in patients with hypoalbuminemia. Pericardial effusion formation in PAH is a known adverse prognostic finding, and the lack of independent association between pericardial effusion and mortality when corrected for serum albumin may suggest that hypoalbuminemia might mediate this finding. 1 These findings help to reinforce the necessity for additional models and variables to predict progression and severity of PAH.
Although traditional indices of functional capacity are reduced among both subsets, additional measures of disease severity with higher sensitivity are necessitated, as demonstrated in recent studies in other patient populations. 25 Several inherent study limitations exist, as with other retrospective observational studies. Only 60% of patients evaluated at our institution during this time period had a serum albumin level documented, although an initial baseline analysis showed no difference in follow-up or outcomes between patients with and without documented serum albumin values. The study institution is a tertiary care academic medical center, and therefore, most patients were diagnosed prior to referral, which will influence time-dependent outcomes. The study population included patients from nearly a decade ago, in the setting of a rapid evolution in the therapeutic armamentarium for PAH, with relatively few patients on PAH-specific therapies at initial evaluation.
Additional laboratory and clinical variables needed to distinguish among the many potential pathophysiologic processes driving hypoalbuminemia in these patients were not available, and it remains possible that certain specific etiologies for hypoalbuminemia might have different prognostic relevance. Further studies are needed to assess the incremental value of serum albumin concentrations in conjunction with various scoring systems. We were not able to consistently calculate validated PAH prognostic risk scores, such as the REVEAL (Registry to Evaluate Early and Long-term PAH Disease Management)
Registry risk score, 3 to determine the incremental prognostic value of serum albumin when added to these established risk models. Although these limitations exist, strengths of our study include a relatively large patient population, comparisons of extensive clinical variables including invasive hemodynamics, and a relatively long follow-up period.
| CONCLUSION
Our study found that lower serum albumin concentrations in patients with PAH are associated with more systemic comorbidities and decreased survival, potentially representing a more progressive clinical course. Although our data suggest that serum albumin concentrations can be used as a nonselective marker for disease severity, further prospective studies are needed to confirm these findings.
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